David P Skoner
Overview
Explore the profile of David P Skoner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
824
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayes B, Mahady S, McGuire A, Sforza A, Sforza J, Piedimonte G, et al.
Pediatr Pulmonol
. 2024 Nov;
60(1):e27327.
PMID: 39513639
Two children, both under the care of specialists for mild persistent asthma, flirted with mortality. One lost and one won the battle. A 16-year-old boy never received ICS therapy despite...
2.
Skoner D, Golant A, Norton A, Stukus D
J Allergy Clin Immunol Pract
. 2022 Aug;
10(12):3064-3072.
PMID: 35963511
All drugs have potential side effects, but thoughtful use can maximize benefits while minimizing risks. Children should not be considered just small adults regarding drug safety because their growth and...
3.
Skoner D, Meltzer E, Skoner J, Sacks H, Lumry W
Allergy Asthma Proc
. 2021 Nov;
43(1):70-77.
PMID: 34753535
Intranasal corticosteroids (INCS) are the cornerstone of treatment for chronic rhinosinusitis. Although INCS are generally considered safe and effective, there is a concern that chronic use may lead to ocular...
4.
Sullivan P, Ghushchyan V, Skoner D, Lecocq J, Park S, Zeiger R
J Allergy Clin Immunol Pract
. 2020 Dec;
9(4):1541-1551.e9.
PMID: 33290914
Background: Limited comparative data are available on the impact of systemic corticosteroid (SCS) use in children and adolescents. Objective: To determine if asthmatic children and adolescents treated with SCS have...
5.
Gentile D, Morphew T, Elliott J, Presto A, Skoner D
J Asthma
. 2020 Oct;
59(1):12-22.
PMID: 33104451
Introduction: Outdoor air pollution (OAP) contributes to poor asthma outcomes and remains a public health concern in Pittsburgh. The purpose of this study was to determine the prevalence of childhood...
6.
Weinstein A, Singh A, Laurenceau J, Skoner D, Maiolo J, Sharara R, et al.
J Allergy Clin Immunol Pract
. 2019 Jan;
7(5):1497-1506.
PMID: 30641146
Background: An Asthma Adherence Pathway (AAP) application, which is an Internet application that combines patient and clinician education strategies to promote adherence to asthma therapy, has been developed. Objective: The...
7.
Goldstein S, Gabriel S, Kianifard F, Ortiz B, Skoner D
Ann Allergy Asthma Immunol
. 2017 Apr;
118(4):500-504.
PMID: 28390587
Background: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL. Objective: To describe the baseline clinical profile...
8.
Skoner D
Ann Allergy Asthma Immunol
. 2016 Dec;
117(6):595-600.
PMID: 27979015
Background: Both slowed growth in children and reduced bone mineral density (BMD) are systemic effects of corticosteroids, and there is concern about the degree to which these systemic effects affect...
9.
Skoner D
Allergy Asthma Proc
. 2016 Mar;
37(3):180-91.
PMID: 26935232
Background: Earlier 1-year growth studies that used older inhaled corticosteroid (ICS) formulations consistently showed that ICS, but not intranasal corticosteroids (INCS), produced a small ∼1 cm/y growth effect that appeared...
10.
Pleskovic N, Bartholow A, Gentile D, Skoner D
Curr Allergy Asthma Rep
. 2015 Jul;
15(8):44.
PMID: 26149585
Sublingual immunotherapy (SLIT) is a safe and effective treatment for allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC). The Food and Drug Administration (FDA) in the USA has approved three SLIT...